Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
Monica Bocchia,1 Angelo Michele Carella,2 Antonino Mulè,3 Lorenzo Rizzo,4 Mauro Turrini,5 Maria Chiara Abbenante,2 Roberto Cairoli,4 Valeria Calafiore,3 Marzia Defina,1 Angelo Gardellini,5 Giovanni Luzi,6 Caterina Patti,3 Maria Beatrice Pinazzi,6 Marta Riva,4 Giovanni Rossi,2 Vincenzo Sammartano,1 L...
Main Authors: | Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V, Rigacci L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-04-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/therapeutic-management-of-patients-with-flt3--acute-myeloid-leukemia-c-peer-reviewed-fulltext-article-PGPM |
Similar Items
-
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01) -
Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia
by: Meira Yisraeli Salman, et al.
Published: (2021-10-01) -
Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
by: Karam Ashouri, et al.
Published: (2024-04-01) -
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
by: Lindsey T. Brinton, et al.
Published: (2020-10-01) -
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
by: Normann Steiner, et al.
Published: (2020-08-01)